Boston Scientific BSX Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net sales of reportable segments by Business | ||||||
| Cardiovascular | $3.5B+1.1% | $3.47B+4.1% | $3.33B-0.4% | $3.34B+5.8% | $3.16B+6.0% | |
| MedSurg | $1.7B-5.7% | $1.8B+5.1% | $1.71B0.0% | $1.71B+6.5% | $1.61B-1.7% | |
| Net Sales by Product | ||||||
| Cardiac Rhythm Management | $578M-1.4% | $586M+1.4% | $578M-2.0% | $590M+2.1% | $578M+2.1% | |
| Electrophysiology | $905M+1.7% | $890M+2.9% | $865M+3.0% | $840M+15.1% | $730M+12.5% | |
| Endoscopy | $736M-3.0% | $759M+1.6% | $747M+1.4% | $737M+9.5% | $673M-2.6% | |
| Interventional Cardiology & Vascular Therapies | $1.24B— | —— | $686M-6.2% | $731M-35.0% | $1.12B+68.3% | |
| Interventional Oncology & Embolization | $268M— | —— | —— | —— | $228M+6.5% | |
| Neuromodulation | $318M-4.5% | $333M+13.7% | $293M-3.3% | $303M+11.8% | $271M-9.4% | |
| Urology | $646M-9.9% | $717M+5.1% | $682M+0.9% | $676M+6.8% | $633M+0.5% | |
| Watchman | $506M-5.4% | $535M+4.5% | $512M+5.3% | $486M+14.4% | $425M+2.9% | |
| Net Sales by Geography | ||||||
| Asia-Pacific | $803M+1.9% | $788M-1.7% | $802M+1.5% | $790M+12.7% | $701M+2.5% | |
| Europe, Middle East and Africa | $932M-0.1% | $933M+17.7% | $793M-9.7% | $878M+3.8% | $846M+1.9% | |
| Latin America and Canada | $185M+3.4% | $179M+2.3% | $175M+3.6% | $169M+9.0% | $155M0.0% | |
| U.S. | $3.28B-3.0% | $3.39B+2.8% | $3.29B+2.2% | $3.22B+8.9% | $2.96B+2.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Boston Scientific break its business down?
- Boston Scientific (BSX) reports net sales of reportable segments by business across 2 parts — Cardiovascular and MedSurg. Each is extracted from the segment footnotes and tracked over time.
- Where does Boston Scientific's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Boston Scientific's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
